As the circadian clock-related prognostic signature showed its performance in predicting survival and exhibited an effect on immune response, we naturally proposed a hypothesis whether the gene signature could reflect the response to molecular targeted therapy in cancer. This evidence concerns the gene CLOCK and cancer.